Viking Therapeutics, Inc. (VKTX) Stock
VKTX Key Statistics
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
CEO: Brian Lian. Company website
VKTX — Frequently Asked Questions
What is the VKTX stock price today?
Viking Therapeutics, Inc. (VKTX) trades at $28.99, down 1.26% on the day, as of Sep 20, 2026 14:57 UTC.
What is Viking Therapeutics, Inc.'s market cap?
Viking Therapeutics, Inc. has a market capitalisation of $3.38B, calculated from the live VKTX share price and shares outstanding.
What is the P/E ratio of VKTX?
VKTX has no meaningful price-to-earnings ratio: Viking Therapeutics, Inc. lost $4.66 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Viking Therapeutics, Inc. make?
Viking Therapeutics, Inc. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for VKTX?
VKTX has traded between $22.96 and $43.15 over the past 52 weeks, and the last price is 32.8% below that high.
Is Viking Therapeutics, Inc. profitable?
Yes. Viking Therapeutics, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for VKTX?
Wall Street analysts rate VKTX Buy, with an average price target of $91.75, 216.5% above the current price.
What sector is Viking Therapeutics, Inc. in?
Viking Therapeutics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Viking Therapeutics, Inc.?
Brian Lian is the chief executive of Viking Therapeutics, Inc., which employs 65 people.
Where can I track VKTX in real time?
QFI Terminal shows VKTX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See VKTX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open VKTX in Terminal See plans